We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00600236
First Posted: January 24, 2008
Last Update Posted: January 24, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Instituto Nacional de Referencia Epidemiológica (INdRE)
Information provided by:
Asociación para Evitar la Ceguera en México
  Purpose
One of the first causes of irreversible blindness in mexican population is diabetic retinopathy which is clearly diferent between patients the time of evolution and development of retinopathy and complications. The aim of this study is to explore the inmunogenetic profile and the influence of HLA in this variations of the sickness to predict the severity of diabetic complications.

Condition Intervention Phase
Diabetes Mellitus Type 2 Proliferative Diabetic Retinopathy Procedure: blood sample Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single
Primary Purpose: Prevention
Official Title: HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population

Resource links provided by NLM:


Further study details as provided by Asociación para Evitar la Ceguera en México:

Estimated Enrollment: 300
Study Start Date: September 2004
Study Completion Date: January 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy
  • Diabetes mellitus type 2 with 10 years of diagnosis and proliferative retinopathy

Exclusion Criteria:

  • Systemic hipertension
  • Cardic disease
  • Lupus
  • Any kind of artritis
  • Allergies
  • Optic Neuritis
  • VKH
  • Cancer
  • Inmunological diseases
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00600236


Locations
Mexico
Asociación para Evitar la Ceguera en México, Hospital "Luis Sanchez Bulnes"
Mexico City, Mexico DF, Mexico, 04030
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México
Instituto Nacional de Referencia Epidemiológica (INdRE)
Investigators
Principal Investigator: Hugo Quiroz-Mercado, MD Asociación para Evitar la Ceguera en México, Hospital "Luis Sánchez Bulnes"
  More Information

ClinicalTrials.gov Identifier: NCT00600236     History of Changes
Other Study ID Numbers: APEC-0018
First Submitted: June 30, 2006
First Posted: January 24, 2008
Last Update Posted: January 24, 2008
Last Verified: January 2008

Keywords provided by Asociación para Evitar la Ceguera en México:
Diabetes mellitus type 2 with 10 years of diagnosis and no diabetic retinopathy
Diabetes mellitus type 2 with 10 years of diagnosis and proliferative diabetic retinopathy

Additional relevant MeSH terms:
Diabetes Mellitus
Retinal Diseases
Diabetic Retinopathy
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications